RxDoctor Payments Data

Ashlea Hannamann, PA

Physician Assistant · Albuquerque, NMNPI 1164998613

Payments from drug & device makers

$1,535in general payments, 2019–2025

Across 60 payments — averaging $25.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$307
  • Lilly USA, LLC$235
  • Amgen$203
  • GSK$189
  • Novo Nordisk$128
  • Boehringer Ingelheim$54
  • plus $418 from 15 others

What the payments were for

  • Food & beverage$1,535100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,535 in reported general payments places this provider in the 85th percentile of 635 physician assistant providers in New Mexico.

See all physician assistant providers in New Mexico

Medicare billing

Part B allowed, 2024
$39,798
Medicare patients
376
Services billed
997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban35$21,867
Advair HfaFluticasone Propion/Salmeterol14$5,047
Ondansetron OdtOndansetron183$1,897
Oxycodone Hcl248$1,674
Dexamethasone178$1,206
Tramadol Hcl210$1,047
Albuterol Sulfate HfaAlbuterol Sulfate26$640
Etodolac35$460
Rosuvastatin Calcium15$372
Oxybutynin Chloride12$343
Pantoprazole Sodium15$225
Cephalexin36$211
Atorvastatin Calcium24$194
Levothyroxine Sodium13$169
Donepezil Hcl12$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$20$21,86735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 635 physician assistant providers in New Mexico.

Other physician assistant in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →